ClinicalTrials.gg
RecruitingNCT05846451Updated Jun 3, 2026

Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints

An Early Phase 1 interventional study of Kratom and Oxycodone in Herbal Interaction, sponsored by Washington State University. Recruiting at 1 site in United States. Open to participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Washington State University · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
21 Years to 45 Years
Sex
All
01

Study summary

The goal of this study is to investigate whether the botanical product kratom affects how the body processes the opioid drug oxycodone. The main research questions to be answered are two-fold:

  1. How does kratom affect the manner in which oxycodone is metabolized (broken down and removed) by the body?
  2. Does kratom change the effects oxycodone exerts on the body?

Healthy adult participants will complete four study arms, during which they will be given the following:

  • Kratom (as a tea)
  • A single dose of oxycodone (as a tablet)
  • Kratom tea and a single dose of oxycodone
  • Kratom tea for four days, then kratom tea and a single dose of oxycodone
Read the detailed description

The primary objective of this study is to evaluate the potential for kratom to precipitate a pharmacokinetic interaction with the common opioid and dual cytochrome P450 (CYP) 3A/CYP2D6 substrate oxycodone. A secondary objective is to evaluate a potential pharmacodynamic interaction by measuring pupil diameter, the most sensitive measure of central nervous system opioid effects. To evaluate these objectives, participants will complete four arms, during which they will be administered the following:

  • Arm 1: a single low dose of kratom (by mouth, as a tea)
  • Arm 2: a single low dose of immediate-release oxycodone (by mouth, as a tablet)
  • Arm 3: a single low dose of kratom tea and a single low dose of oxycodone
  • Arm 4: daily at-home self-administration of kratom tea for four days, followed immediately by a single low dose of kratom tea and a single low dose of oxycodone in the research setting
02

Conditions studied

  • Herbal Interaction

Keywords

  • pharmacokinetic
  • pharmacokinetics
  • pharmacodynamic
  • pharmacodynamics
  • kratom
  • oxycodone
  • natural product
  • botanical product
  • natural product-drug interaction
  • mitragynine
03

In context

Lead sponsor

Washington State University is the lead sponsor of 83 studies on the registry; 16 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females, aged from 21-45 years and healthy
  • Body weight between 130 and 250 pounds (60-115 kg) and between 19 and 30
  • Not taking any medications (prescription and non-prescription) or dietary supplements/botanical products known to alter the pharmacokinetics of either oxycodone or kratom
  • Willing to abstain from consuming dietary supplements/botanical products and fruit juices for several weeks
  • Willing to abstain from cannabis/marijuana, hemp, and THC- and/or CBD-containing products for several weeks
  • Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient visit
  • Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient visit
  • Willing to use an additional method of that does not include oral contraceptive pills, patches, or other hormonal methods (such as abstinence, copper IUD, or condoms)
  • Have consumed kratom previously and tolerated it well without any unpleasant effects
  • Willing to abstain from kratom for several weeks
  • Have consumed any opioid previously and tolerated it well without any unpleasant effects or addiction
  • Written (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study
  • Geographically located within a 40-mile radius of Spokane and have the time to participate

Exclusion criteria

Exclusion Criteria:

  • Males and females under the age of 21 or over the age of 45
  • People who weigh less than 130 pounds or more than 250 pounds
  • People with a less than 19 or greater than 30
  • Any current major illness or chronic illness including but not limited to kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, , cancer, or /AIDS
  • No previous exposure to kratom
  • No previous exposure to an opioid
  • History of anemia or any other significant hematologic disorder
  • History of substance abuse, dependence, or addiction or major psychiatric illness
  • A need for chronic opioid analgesics
  • Use of opioid analgesics 3 weeks prior to initiation of the study
  • An imminent likely need for opioid analgesics (e.g., planned dental or surgical procedure)
  • Pregnant or nursing
  • History of allergy or intolerance to kratom, other opioids, or oxycodone
  • Taking concomitant medications, both prescription and non-prescription (including dietary supplements/botanical products), known to alter the pharmacokinetics of kratom or oxycodone
  • Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data
  • History of sleep apnea
  • Any prior use of amphetamines, benzodiazepines, cocaine, MDMA, opioids, PCP, or other drugs for recreational purposes
  • Use of cannabis/marijuana, hemp, THC-containing products, CBD-containing products, or CBD within the last month
  • Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk
  • Inability to speak, read, and understand English
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Sixteen non-naive\* participants (8 males, 8 females) will be administered a single low dose (2 g) of a well-characterized kratom product by mouth as a tea. Pupil diameter will be measured from 0-12 hours. A washout of at least 10 days will separate Arms 1 and 2. \*Non-naive subjects are defined as intermittent users who consume 2-8 g kratom at least once per month but no more than three times daily within the last six months prior to screening and are willing to abstain for several weeks

    Dietary Supplement: Kratom

  • Active comparator
    Arm 2

    The same 16 participants will be administered a single low dose (10 mg) of immediate-release oxycodone by mouth as a tablet. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 2 days will separate Arms 2 and 3.

    Drug: Oxycodone

  • Experimental
    Arm 3

    The same 16 participants will be administered a single low dose (2 g) of kratom as a tea. After 15 minutes, the subjects will be administered a single low dose (10 mg) of oxycodone as a tablet by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours. A washout of at least 10 days will separate Arms 3 and 4.

    Dietary Supplement: Kratom · Drug: Oxycodone

  • Experimental
    Arm 4

    The same 16 participants will self-administer a single low dose (2 g) of kratom as a tea once daily at home. On the fifth day, subjects will return to the research setting, where they will be administered a single low dose (2 g) of kratom, followed 15 minutes later by a single low dose (10 mg) of oxycodone by mouth. Plasma, pupil diameter measurements, and urine will be collected from 0-24 hours.

    Dietary Supplement: Kratom · Drug: Oxycodone

Interventions

  • Dietary supplementKratom

    Kratom (Moon Kratom Yellow Indonesian, lot 51) is supplied as a dry leaf powder in clear plastic bags, each weighing 5 kg. Two grams of kratom dry leaf powder will be stirred into 240 mL of hot water to make a tea. The tea will be cooled to 50 degrees Celsius before administration. Participants will drink the tea within 15 minutes.

  • Immediate-release oral tablet, 10 mg

06

What researchers measure

Primary outcomes

  1. Oxycodone area under the concentration vs. time curve (AUC) ratio (presence to absence of kratom)

    Ratio of the AUC of oxycodone in the presence to absence of kratom.

    Time frame: 0-24 hours

Secondary outcomes

  1. Area under the pupil diameter (effect) vs. time curve (AUEC) ratio

    Ratio of AUEC in presence of oxycodone+kratom to oxycodone

    Time frame: 0-24 hours

  2. Oxycodone maximum plasma concentration (Cmax) ratio (presence to absence of kratom)

    Ratio of Cmax of oxycodone in the presence to absence of kratom.

    Time frame: 0-24 hours

  3. Oxycodone half-life ratio (presence to absence of kratom)

    Ratio of half-life of oxycodone in the presence to absence of kratom

    Time frame: 0-24 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Nov 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05846451
Lead sponsor
Washington State University
Responsible party
Mary Paine (Professor, Washington State University) — Principal investigator
First posted
May 6, 2023
Start date
Jun 1, 2023
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Mary Paine, PhD
Contact
mary.paine@wsu.edu
509-358-7759
Deena Hadi, BS
Contact
deena.hadi@wsu.edu
509-368-6692

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mitragyna speciosa leaf · Oxycodone

Start the discussion